Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
주식 순위 #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
주가
$0.00047446
시가총액
$82.80
변동 (1일)
0.00%
변동 (1년)
-98.16%
국가
FR
거래 Neovacs S.A. (ALNEV)

카테고리

Neovacs S.A. (ALNEV)의 발행 주식 수
December 2024 기준 발행 주식 수: 174.51K
Neovacs S.A.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 174.51K입니다. December 2023 말 기준 회사는 35.17주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Neovacs S.A. (ALNEV)의 발행 주식 수 기록 (2007 ~ 2026)
매년 말 기준 발행 주식 수
연도 발행 주식 수 변화
2026 (TTM) 174.51K 0.00%
2024 174.51K 496,123.88%
2023 35.17 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
유사 기업 또는 경쟁사의 발행 주식 수
회사 발행 주식 수 차이 국가
4.45B 2,548,607.27%
DK
253.90M 145,389.76%
US
102.90M 58,863.75%
US
190.00M 108,772.07%
BE
61.42M 35,094.31%
NL